These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33641235)

  • 1. Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
    Sukmawan R; Hoetama E; Suridanda Danny S; Giantini A; Listiyaningsih E; Gilang Rejeki V; Aziz Alkatiri A; Firdaus I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00738. PubMed ID: 33641235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
    Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
    Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
    JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK
    BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
    He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
    Peng W; Shi X; Xu X; Lin Y
    Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al-Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Loza BL; Claassens DMF; Asselbergs FW; Al-Ali AK
    Int J Cardiol; 2021 Nov; 343():15-20. PubMed ID: 34506827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    Palmerini T; Calabrò P; Piscione F; De Servi S; Cattaneo M; Maffeo D; Toso A; Bartorelli A; Palmieri C; De Carlo M; Capodanno D; Barozzi C; Tomasi L; Della Riva D; Mariani A; Taglieri N; Reggiani LB; Bianchi R; De Rosa R; Mariani M; Podda G; Généreux P; Stone GW; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1117-27. PubMed ID: 25240538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
    Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
    J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
    Li X; Wang Z; Wang Q; Xu Q; Lv Q
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):84-93. PubMed ID: 30098132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
    Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L
    Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Jiang Z; Zhang R; Sun M; Liu Q; Wang S; Wang W; Zhao Q; Zhang H; Wang Y; Hou J; Yu B
    Can J Cardiol; 2018 Dec; 34(12):1606-1612. PubMed ID: 30527148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI.
    Erathi HV; Durgaprasad R; Velam V; Pvgk S; Rodda M; C K; Kanavath SN
    Minerva Cardioangiol; 2018 Feb; 66(1):16-25. PubMed ID: 28752728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
    JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.